These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28625521)

  • 1. Protective efficacy of multivalent replication-abortive vaccine strains in horses against African horse sickness virus challenge.
    Lulla V; Losada A; Lecollinet S; Kerviel A; Lilin T; Sailleau C; Beck C; Zientara S; Roy P
    Vaccine; 2017 Jul; 35(33):4262-4269. PubMed ID: 28625521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform.
    van Rijn PA; Maris-Veldhuis MA; Potgieter CA; van Gennip RGP
    Vaccine; 2018 Apr; 36(15):1925-1933. PubMed ID: 29525278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV.
    van de Water SG; van Gennip RG; Potgieter CA; Wright IM; van Rijn PA
    J Virol; 2015 Sep; 89(17):8764-72. PubMed ID: 26063433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assembly of Replication-Incompetent African Horse Sickness Virus Particles: Rational Design of Vaccines for All Serotypes.
    Lulla V; Lulla A; Wernike K; Aebischer A; Beer M; Roy P
    J Virol; 2016 Aug; 90(16):7405-7414. PubMed ID: 27279609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entry-competent-replication-abortive African horse sickness virus strains elicit robust immunity in ponies against all serotypes.
    Sullivan E; Lecollinet S; Kerviel A; Hue E; Pronost S; Beck C; Dumarest M; Zientara S; Roy P
    Vaccine; 2021 May; 39(23):3161-3168. PubMed ID: 33958224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.
    Manning NM; Bachanek-Bankowska K; Mertens PPC; Castillo-Olivares J
    Vaccine; 2017 Oct; 35(44):6024-6029. PubMed ID: 28438410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus.
    Guthrie AJ; Quan M; Lourens CW; Audonnet JC; Minke JM; Yao J; He L; Nordgren R; Gardner IA; Maclachlan NJ
    Vaccine; 2009 Jul; 27(33):4434-8. PubMed ID: 19490959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic DIVA tests accompanying the Disabled Infectious Single Animal (DISA) vaccine platform for African horse sickness.
    van Rijn PA; Maris-Veldhuis MA; Boonstra J; van Gennip RGP
    Vaccine; 2018 Jun; 36(25):3584-3592. PubMed ID: 29759377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of African horse sickness virus nucleic acid and antibody in horses following immunization with a commercial polyvalent live attenuated vaccine.
    Weyer CT; Grewar JD; Burger P; Joone C; Lourens C; MacLachlan NJ; Guthrie AJ
    Vaccine; 2017 Apr; 35(18):2504-2510. PubMed ID: 28341113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reverse genetics approaches: a novel strategy for African horse sickness virus vaccine design.
    Calvo-Pinilla E; Marín-López A; Utrilla-Trigo S; Jiménez-Cabello L; Ortego J
    Curr Opin Virol; 2020 Oct; 44():49-56. PubMed ID: 32659516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ns1 is a key protein in the vaccine composition to protect Ifnar(-/-) mice against infection with multiple serotypes of African horse sickness virus.
    de la Poza F; Calvo-Pinilla E; López-Gil E; Marín-López A; Mateos F; Castillo-Olivares J; Lorenzo G; Ortego J
    PLoS One; 2013; 8(7):e70197. PubMed ID: 23894615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly efficient vaccines for Bluetongue virus and a related Orbivirus based on reverse genetics.
    Roy P
    Curr Opin Virol; 2020 Oct; 44():35-41. PubMed ID: 32610251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses.
    El Garch H; Crafford JE; Amouyal P; Durand PY; Edlund Toulemonde C; Lemaitre L; Cozette V; Guthrie A; Minke JM
    Vet Immunol Immunopathol; 2012 Sep; 149(1-2):76-85. PubMed ID: 22763149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serological response of foals to polyvalent and monovalent live-attenuated African horse sickness virus vaccines.
    Crafford JE; Lourens CW; Smit TK; Gardner IA; MacLachlan NJ; Guthrie AJ
    Vaccine; 2014 Jun; 32(29):3611-6. PubMed ID: 24814557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host.
    Calvo-Pinilla E; Gubbins S; Mertens P; Ortego J; Castillo-Olivares J
    Antiviral Res; 2018 Jun; 154():132-139. PubMed ID: 29678552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara.
    Marín-López A; Barreiro-Piñeiro N; Utrilla-Trigo S; Barriales D; Benavente J; Nogales A; Martínez-Costas J; Ortego J; Calvo-Pinilla E
    Vaccine; 2020 Jan; 38(4):882-889. PubMed ID: 31708178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral susceptibility of South African Culicoides species to live-attenuated serotype-specific vaccine strains of African horse sickness virus (AHSV).
    Paweska JT; Prinsloo S; Venter GJ
    Med Vet Entomol; 2003 Dec; 17(4):436-47. PubMed ID: 14651659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation.
    Calvo-Pinilla E; de la Poza F; Gubbins S; Mertens PP; Ortego J; Castillo-Olivares J
    Virus Res; 2014 Feb; 180():23-30. PubMed ID: 24333835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model.
    Aksular M; Calvo-Pinilla E; Marín-López A; Ortego J; Chambers AC; King LA; Castillo-Olivares J
    Vaccine; 2018 Nov; 36(46):7003-7010. PubMed ID: 30309744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of inactivated African horse sickness (AHS) vaccine formulated with different adjuvants.
    van Rijn PA; Maris-Veldhuis MA; Grobler M; Wright IM; Erasmus BJ; Maartens LH; Potgieter CA
    Vaccine; 2020 Oct; 38(45):7108-7117. PubMed ID: 32921506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.